Gilbert H Tang, MD Email Gilbert Tang
- SENIOR FACULTY | Cardiovascular Surgery
- Cardiovascular Surgery
- Chinese (Cantonese)
- Chinese (Mandarin)
- Hospital Affiliations
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
- Cardiovascular Surgery 212-659-6800212-659-6800
Dr. Gilbert Tang is currently the Surgical Director of the Structural Heart Program at the Mount Sinai Health System. He has performed over 1000 cases of transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (MitraClip) procedures with excellent outcomes, on par with some of the top programs in the country. Dr. Tang has achieved many “first” successes in the region and United States, including transcatheter mitral and tricuspid valve replacement and tricuspid valve repair with MitraClip, all performed via the groin without open surgery. Prior to Mount Sinai, Dr. Tang was the Director of the Valve Disease Center at Westchester Medical Center, playing a pivotal role in the launch of their Transcatheter Heart Program. His “concierge” model of care has been well received and recognized in the New York area.
As a regularly invited faculty and guest lecturer at national and international conferences, Dr. Tang is leading a number of cutting-edge research projects in TAVR and transcatheter mitral and tricuspid valve therapies. He pioneered a technique to help better orient a transcatheter heart valve during TAVR to make it easier to reaccess the coronary arteries. His research and clinical results have been published in many top peer-reviewed medical journals and presented at many international conferences. He has trained many physicians and heart teams to perform transcatheter valve procedures around the world. He is currently involved in several multicenter studies with leading institutions in the US and globally.
Dr. Tang received his bachelor's degree at Harvard University and MD at the University of Toronto, where he completed his residency in cardiac surgery as the Chief Resident at the Toronto General Hospital. He completed a Master of Science in tissue engineering at the University of Toronto and an MBA at the Harvard Business School. Dr. Tang pursued specialized training at Mount Sinai Medical Center in New York focusing on complex mitral valve repair and TAVR. He also underwent advanced training in TAVR at the Leipzig Heart Center in Germany and the University of Pennsylvania. Dr. Tang is a Diplomat and Fellow of the Royal College of Physicians and Surgeons of Canada.
The New York Times: Tiny Device Is a “Huge Advance” for Treatment of Severe Heart Failure, 9/23/18
The results have left leading researchers unexpectedly optimistic. The trial sends “a very, very powerful message,” said Dr. Gilbert Tang, a heart surgeon at Mount Sinai Medical Center, which enrolled a patient in the trial.
Not so fast, said Gilbert Tang, MD (Mount Sinai Health System/Icahn School of Medicine, New York, NY), who took the stage after Feldman. Or at least, “not yet.”
Percutaneous procedures, at least for now, do not offer the variety of approaches that surgery can offer, he argued, pointing out that MR comes in myriad forms. Different MR etiology, mitral lesions, and patient risk profile all play an important role. And while transcatheter therapies have evolved to approximate edge-to-edge, annuloplasty, and chordal replacement procedures, no percutaneous therapy is able to perform resection and reconstruction, a common surgical technique, Tang said.
- Aortic Insufficiency
- Aortic Regurgitation
- Aortic Stenosis
- Heart Failure
- Heart Murmur
- Mitral Regurgitation
- Mitral Stenosis
- Mitral Valve Disease
- Tricuspid Valve Disease
- Valvular Heart Disease
BA, Harvard University
MD, University of Toronto
MBA, Harvard Business School
MSc, University of Toronto
Residency, Cardiac Surgery
University of Toronto
Chinese (Cantonese), Chinese (Mandarin), English
New York Society for Thoracic Surgery
Transcatheter heart valve, valvular heart disease
Tang GH, Zaid S, Ahmad H, Al E. Transcatheter Valve Neo-Commissural Overlap With Coronary Orifices After Transcatheter Aortic Valve Replacement. Circulation. Cardiovascular interventions 2018 Oct; 11(10).
TANG G, KAPLE R, COHEN M, DUTTA T, UNDEMIR C, AHMAD H, PONIROS A, BENNETT J, FENG C, LANSMAN S. First percutaneous Micra leadless pacemaker implantation and tricuspid valve repair with MitraClip NT for lead-associated severe tricuspid regurgitation. Eurointervention 2017;.
Tang GH, Ong LY, Kaple R, Ramlawi B, Dutta T, Zaid S, Ahmad H, Kalimi R, Undemir C, Khan A, Yudi MB, Nadir MA, Majeed F, Ali O, Skiles J, Bhim C, Cohen M, Lansman SL, Sharma SK, Kini A. Continuous invasive hemodynamic monitoring using steerable guide catheter to optimize mitraclip transcatheter mitral valve repair: A multicenter, proof-of-concept study. Journal of interventional cardiology 2018 Aug;.
Tang GH, Zaid S, George I, Khalique OK, Abramowitz Y, Maeno Y, Makkar RR, Jilaihawi H, Kamioka N, Thourani VH, Babaliaros V, Webb JG, Htun NM, Attinger-Toller A, Ahmad H, Kaple R, Sharma K, Kozina JA, Kaneko T, Shah P, Hirji SA, Desai ND, Anwaruddin S, Jagasia D, Herrmann HC, Basra SS, Szerlip MA, Mack MJ, Mathur M, Tan CW, Don CW, Sharma R, Gafoor S, Zhang M, Kapadia SR, Mick SL, Krishnaswamy A, Amoroso N, Salemi A, Wong SC, Kini AS, Rodés-Cabau J, Leon MB, Kodali SK. Impact of Aortic Root Anatomy and Geometry on Paravalvular Leak in Transcatheter Aortic Valve Replacement With Extremely Large Annuli Using the Edwards SAPIEN 3 Valve. JACC. Cardiovascular interventions 2018 Jul; 11(14).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Tang did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.